TABLE 1.
Characteristics of patient demographics, dosing history, and TDM data for model development (UUH data set) and external validation (EWUSH data set)d
| Characteristics | UUHa | EWUSHa |
|---|---|---|
| Number of subjects | 580 | 163 |
| Male sex, N (%) | 362 (62.4) | 95 (58.3) |
| Age, years | 68 (57, 77) | 72 (60, 80) |
| Body weight, kg | 60.0 (52.1, 67.7) | 57.7 (49.6, 67.7) |
| Height, cm | 163 (156, 170) | 163 (155, 170) |
| Body mass index, kg/m2 | 22.6 (20.4, 25.3) | 22.2 (19.5, 24.7) |
| Serum creatinine, mg/dL | 0.67 (0.52, 0.86) | 0.60 (0.46, 0.82) |
| eGFRb, mL/min/1.73 m2 | 96.3 (81.9, 107.8) | 97.9 (79.7, 115.0) |
| Number of treatment episodes | 647 | 172 |
| Number of TDM occasions | 1,034 | 326 |
| Single dose, mg | 1,000 (800, 1000) | 750 (550, 1,000) |
| Vancomycin dosing interval, N (%) | ||
| 3 hours | - | 2 (0.6) |
| 4 hours | - | 14 (4.3) |
| 6 hours | 2 (0.2) | 58 (17.8) |
| 8 hours | 27 (2.6) | 51 (15.6) |
| 12 hours | 945 (91.4) | 179 (54.9) |
| 18 hours | 16 (1.5) | - |
| 24 hours | 43 (4.2) | 22 (6.7) |
| 48 hours | 1 (0.1) | - |
| Infusion duration, N (%) | ||
| 1 hour | 997 (96.4) | 326 (100) |
| 1.3 hour | 1 (0.1) | - |
| 1.5 hour | 6 (0.6) | - |
| 2 hour | 30 (2.9) | - |
| Daily dose per weight, mg/kg/day | 30.6 (25.9, 35.9) | 31.1 (22.5, 42.9) |
| AUC24 by the Bayesian method, mg∙hr/L | 484.5 (381.9, 591.7) | 560.2 (441.8, 684.8) |
| Number of trough concentrations | 1,034 | 326 |
| Number of non-trough concentrationsc | 75 | 326 |
| Measured trough concentration, mg/L | 12.6 (8.8, 17.1) | 16.7 (11.5, 21.1) |
a
Number (%) or median (Q1; Q3).
b
Calculated by the 2009 CKD-EPI equation.
c
Used concentration data with the sampling time outside of the trough definition (sampled within ±1 h of the scheduled time for the next dose). In the EWUSH dataset, they were all post-distributional peak concentrations (1–3 hours post-infusion).
d
AUC24, area under the concentration–time curve normalized to 24 hours; eGFR, estimated glomerular filtration rate; MRSA, methicillin-resistant Staphylococcus aureus; TDM, therapeutic drug monitoring.